Today I thought it would be a good idea to answer a question sent in by a premium subscriber.  He asked,

“What’s the deal with TIL and how does that relate to checkpoint inhibitors and PD-L1 expression?”

This is a good question and there were some interesting top-line debates about this at AACR recently, which are well worth discussing and highlighting.

To learn more insights on this intriguing topic, subscribers can log-in or you can purchase access to BSB Premium Content. 

This content is restricted to subscribers

Posted by